Skin Cancer

Researchers identified several dermoscopic features associated with genes LINC00518, PRAME, and TERT.

Researchers said responses may depend on prior immunotherapy.

Data from the KEYNOTE-942 trial was presented at the American Association for Cancer Research Annual Meeting 2023.

Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.

The PD-1 inhibitor pembrolizumab has proven its efficacy in a number of different cancers.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

A new survey found that the demographics are not following safe sun habits and have low skin cancer awareness.

Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.

In a recent review, authors explored the effects of targeted therapies and immune checkpoint inhibitors on melanoma, particularly in minimal residual disease.

With the advent of immunotherapy, the 1-year survival rate for patients with metastatic melanoma has increased from 25% to 50%.

Patients in the clinical trial had confirmed disease progression after 12 weeks.

Researchers said the pandemic played a role in healthcare providers’ ability to safely and promptly treat various skin cancers.

There are currently no FDA approved therapies in this treatment setting.

The UK and Netherlands study assessed tumor response rates among 91 patients.

DermaSensor’s handheld device is awaiting FDA review.

Researchers were unable to determine a definite correlation.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individual’s risk of developing skin cancer.

Patients with squamous cell carcinoma who experience immunosuppression are at a greater risk.

Anna Bar, MD, FAAD returns to AAD as part of the interactive “How Would You Reconstruct It?” session.

Click here to answer this week's poll.

The commander-in-chief’s cancerous tissue was successfully removed last month.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

The drug used to treat several dermatological disorders has immunosuppressive effects and has been linked with photosensitizing properties.